AMSTERDAM, Dec. 6, 2023 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the expansion of its licensing agreement with Innovent Biologics (Innovent), Inc. (HKEX:01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases.
Mere days after announcing that trials for its lead IL-15 asset have been halted over poor data, Sotio Biotech has unveiled plans to delve deeper into antibody-drug conjugates (ADCs) courtesy of deal worth $740 million in biobucks.
AMSTERDAM, Oct. 12, 2023 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN), focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its Founder and head of R&D, prof. Floris van Delft, will present data on the launch of two new technologies during a plenary session at the World ADC conference in San Diego, at 8.15 am PDT on Wednesday 18 October 2023.
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has acquired Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage technology platform for the development of ADCs.
Just over a year ago, Synaffix and MacroGenics unveiled their antibody drug-conjugate (ADC) collaboration worth up to $586 million for three programs. Now, with interest in the modality ablaze, the two are widening the scope of the deal.
A day after buzzing Hummingbird Bioscience for an antibody-drug conjugate licensing pact, Synaffix is back with a substantially similar, yet bigger deal. The Amsterdam-headquartered biotech will work with Amgen in a pact valued at up to $2 billion.
Hummingbird Bioscience and Synaffix are flocking together in a new $150 million licensing pact that aims to develop a next-gen ADC.
AMSTERDAM, Nov. 16, 2022 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded 'Biotech Company of the Year 2022' at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK.
AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022.
Synaffix has landed another antibody-drug conjugate (ADC) partner. After inking deals with Genmab and MacroGenics this year alone, the Dutch biotech has landed a partnership with Emergence Therapeutics that could be worth $360 million.